Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 12/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | F11 | P03951 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6078656 | 0.81 | F2 (0.47) | F2ALDH1A1LMNAGPBAR1CYP3A4 | |
| SCHEMBL6079352 | 0.80 | F2 (0.46) | F2ALDH1A1LMNAGPBAR1MEN1 | |
| Hydrochloric Acid SCHEMBL6079141 | 0.80 | F2 (0.46) | F2ALDH1A1LMNAGPBAR1CYP3A4 | |
| SCHEMBL6076566 | 0.76 | F2 (0.65) | F2ALDH1A1LMNACYP3A4F11 | |
| SCHEMBL6078072 | 0.74 | F2 (0.60) | F2ALDH1A1LMNACYP3A4F11 | |
| SCHEMBL6079238 | 0.74 | F2 (0.51) | F2ALDH1A1LMNACYP3A4F11 | |
| SCHEMBL1837913 | 0.72 | F2 (0.43) | F2CYP3A4F11 | |
| SCHEMBL6921701 | 0.72 | GPBAR1 (0.45) | F2GPBAR1CYP3A4F11 | |
| SCHEMBL6918685 | 0.70 | MAOA (0.44) | F2GPBAR1CYP3A4F11 | |
| SCHEMBL6078117 | 0.70 | F2 (0.45) | F2ALDH1A1LMNACYP3A4F11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144899-B2 | Thrombin inhibitors | MERCK & CO., INC. (US) | 2006-12-05 | — | — | US | disclosed |
| US-20040073025-A1 | Thrombin inhibitors | MERCK SHARP & DOHME CORP. | 2004-04-15 | — | — | US | disclosed |
| EP-1235550-A2 | NEW COLOURING COMBINATION | Henkel Kommanditgesellschaft auf Aktien (DE) | 2002-09-04 | — | — | EP | disclosed |
| WO-2002064559-A2 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-08-22 | — | — | WO | disclosed |
| WO-2001041717-A2 | NEW COLOURING COMBINATION | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2001-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040073025-A1 | Thrombin inhibitors | F2, F11, F10 | F2 1/4885ALDH1A1 2954/4885LMNA 1769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.